ACTIVE PHARMACEUTICAL INGREDIENTS INDUSTRY:

The global active pharmaceutical ingredients market is predicted to increase at a CAGR of 6.6 percent over the next few years. Advances in active pharmaceutical ingredient (API) manufacture, as well as the increased prevalence of chronic conditions including cardiovascular disease and cancer, are both contributing to the growth. Government regulations that encourage API development, as well as changes in geopolitical situations, are propelling the market forward. The market is likely to be driven by reasons such as an ageing population, rising healthcare spending per capita, rising cancer patients, an inclining orphan drug industry, and rapid outsourcing of API pharmaceuticals. In emerging markets, the pharmaceutical business has seen tremendous expansion. Pharmaceutical demand is being boosted by rising affordability, longer life expectancy, and a higher level of living. As blockbuster pharmaceuticals become less popular, more flexible production centred on individualised therapy may be considered as the pharmaceutical industry’s future. With upcoming approvals of blockbuster or generic medications whose production and supply can only function smoothly using APIs, the pharmaceutical industry has recently entered uncharted terrain. These are biologically active compounds that are put into excipients, which are used to deliver the medication to the patient.

COVID-19 Impact on the Active Pharmaceutical Ingredients Market:

Following the World Health Organization’s declaration of the COVID-19 outbreak as a pandemic, a number of established pharmaceutical and biopharmaceutical companies, as well as tiny startups, have stepped forward to explore therapies for the virus. Scientists discovered a list of compounds that target COVID-19 in just a few weeks. Currently, there are approximately 155 compounds in clinical trials and 45 molecules in preclinical studies to combat COVID-19. Four promising medications have been repurposed for treatment against COVID-19 (Remdesivir, Chloroquine & Hydroxychloroquine, Lopinavir & Ritonavir, and Lopinavir with Ritonavir with Interferon beta-1a). The WHO stated on March 24, 2020 that it had started a worldwide mega trial of the four most promising COVID-19 medicines. Countries are competing in a worldwide race to develop and mass-produce an effective COVID-19 vaccine. The financial and societal costs of pandemics have encouraged governments around the world to increase financing for vaccine development. According to the WHO, there were approximately 140 vaccines in various phases of development as of June 2020. Thirteen of these are presently in human clinical trials, while the rest are still in the early stages of preclinical testing. Increased investment and research for pharmaceutical product development will propel the market forward. It is predicted to have a short-term influence on the market for active medicinal components.

THE INDIAN API INDUSTRY:

The Indian API sector is expected to increase at an annual rate of 8.57 percent. The rising prevalence of chronic diseases such as cancer and cardiovascular diseases (CVDs), the presence of several medium to large API manufacturers, and the government’s increased focus on the development of the pharmaceutical manufacturing sector are all contributing to the country’s API market’s growth. According to the Uttarakhand government, India has a 20 percent volume market share in the worldwide generic industry and a network of more than 10,500 manufacturers and 3,000 pharmaceutical businesses. The Indian API market is divided into four categories: synthesis type, manufacturer type, therapies, and geography. India’s pharmaceutical sector is one of the world’s top suppliers of low-cost generic medicines and vaccines, delivering 20% of total global demand by volume and 62% of global vaccine demand. India is the world’s third-largest producer of pharmaceuticals by volume and the fourteenth-largest by value.

TOP PLAYERS WORLDWIDE:

• Cipla
• Merck & Co.
• Albemarle Corporation
• Pfizer Inc
• Glenmark Pharmaceuticals Limited
• Cytiva
• Natco Pharma
• Apollo Pharmaceuticals API Manufacturers India Pvt. Ltd.
• Novartis
• Divis Laboratories
• Aarti Drugs
• Sanofi
• Hikal
• Neuland Labs
• Abbvie
• Aurobindo Pharma
• Viatris Inc. (formerly Mylan N.V.)